선택적 에스트로겐 수용체 조절제: 작용 기전 및 임상 자료의 고찰

키워드

참고문헌 (71)

1. Bolognese MA, "SERMs and SERMs with estrogen for postmenopausal osteoporosis", Rev Endocr Metab Disord, 11, pp.253~259 (2010)
2. Komm BS, "An overview of current and emerging SERMs", J Steroid Biochem Mol Biol, 143, pp.207~222 (2014)
3. Maximov PY, "The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice", Curr Clin Pharmacol, 8, pp.135~155 (2013)
4. Mirkin S, "Selective estrogen receptor modulators (SERMs): A review of clinical data", Maturitas, 80, pp.52~57 (2015)
5. Pinkerton JV, "Use of SERMs for treatment in postmenopausal women", J Steroid Biochem Mol Biol, 142, pp.142~154 (2014)
6. Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
7. Acconcia F, "Survival versus apoptotic 17betaestradiol effect: Role of ER alpha and ER beta activated non-genomic signaling", J Cell Physiol, 203, pp.193~201 (2005)
8. Williams C, "Oestrogen receptors in breast cancer: Basic mechanisms and clinical implications", Ecancermedicalscience, 7, pp.370~ (2013)
9. McDonnell DP, "The molecular pharmacology of estrogen receptor modulators: Implications for the treatment of breast cancer", Clin Cancer Res, 11, pp.871s~877s (2005)
10. Wardell SE, "From empirical to mechanism-based discovery of clinically useful selective estrogen receptor modulators (SERMs)", Steroids, 90, pp.30~38 (2014)
11. McDonnell DP, "Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens", Mol Endocrinol, 9, pp.659~669 (1995)
12. Taranta A, "The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro", Bone, 30, pp.368~376 (2002)
13. Hofbauer LC, "The OPG", RANKL, J Musculoskelet Neuronal Interact, pp.2004, 4[DOI]
14. Nelson ER, "The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols:Implications for the treatment and prevention of osteoporosis", Bone, 53, pp.42~50 (2013)
15. Jordan VC, "Selective estrogen receptor modulation:Concept and consequences in cancer", Cancer Cell, 5, pp.207~213 (2014)
16. Pinkerton JV, "Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene", conjugated estrogens: A randomized, controlled trial, 2009, pp.16, 1116~1124
17. Kagan R, "A randomized, placebo- and active-controlled trial of bazedoxifene", conjugated estrogens for treatment of moderate to severe vulvar, Menopause, pp.2010, 17[DOI]
18. Mirkin S, "Effects of bazedoxifene", conjugated estrogens on endometrial safety and bone in postmenopausal women, 2013, pp.16, 338~346
19. Pinkerton JV, "Breast effects of bazedoxifene-conjugated estrogens: A randomized controlled trial", Obstet Gynecol, 121, pp.959~968 (2013)
20. Lufkin EG, "Antiresorptive treatment of postmenopausal osteoporosis: Review of randomized clinical studies and rationale for the evista alendronate comparison (EVA) trial", Curr Med Res Opin, 20, pp.351~357 (2014)
21. Gizzo S, "Update on raloxifene:Mechanism of action, clinical efficacy, adverse effects, and contraindications", Obstet Gynecol Surv, 68, pp.467~481 (2013)
22. Pinkerton JV, "Endometrial safety: A key hurdle for selective estrogen receptor modulators in development", Menopause, 17, pp.642~653 (2010)
23. Cuzick J, "Overview of the main outcomes in breast-cancer prevention trials", Lancet, 361, pp.296~300 (2003)
24. Davies C, "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial", Lancet, 381, pp.805~816 (2013)
25. Love RR, "Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer", N Engl J Med, 326, pp.852~856 (1992)
26. O'Regan RM, "Tamoxifen to raloxifene and beyond", Semin Oncol, 28, pp.260~273 (2001)
27. Cohen I, "Endometrial pathologies associated with postmenopausal tamoxifen treatment", Gynecol Oncol, 94, pp.256~266 (2004)
28. Fisher B, "Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the national surgical adjuvant breast and bowel project (NSABP) B-14", J Natl Cancer Inst, 86, pp.527~537 (1994)
29. Deitcher SR, "The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: A systematic review", Cancer, 101, pp.439~449 (2004)
30. Clemett D, "Raloxifene: A review of its use in postmenopausal osteoporosis", Drugs, 60, pp.379~411 (2000)
31. Cummings SR, "The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. multiple outcomes of raloxifene evaluation", JAMA, 281, pp.2189~2197 (1999)
32. Ettinger B, "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. multiple outcomes of raloxifene evaluation (MORE) investigators", JAMA, 282, pp.637~645 (1999)
33. Cauley JA, "Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. multiple outcomes of raloxifene evaluation", Breast Cancer Res Treat, 65, pp.125~134 (2001)
34. Delmas PD, "Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial", J Clin Endocrinol Metab, 87, pp.3609~3617 (2002)
35. Martino S, "Continuing outcomes relevant to evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene", J Natl Cancer Inst, 96, pp.1751~1761 (2004)
36. Siris ES, "Skeletal effects of raloxifene after 8 years: Results from the continuing outcomes relevant to evista (CORE)study", J Bone Miner Res, 20, pp.1514~1524 (2005)
37. Barrett-Connor E, "Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women", N Engl J Med, 355, pp.125~137 (2006)
38. Vogel VG, "Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes:The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial", JAMA, 295, pp.2727~2741 (2006)
39. Martino S, "Safety assessment of raloxifene over eight years in a clinical trial setting", Curr Med Res Opin, 21, pp.1441~1452 (2005)
40. Delmas PD, "Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women", N Engl J Med, 337, pp.1641~1647 (1997)
41. Barrett-Connor E, "Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (multiple outcomes of raloxifene evaluation)randomized trial", JAMA, 287, pp.847~857 (2002)
42. Neven P, "Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of euralox 1", Maturitas, 52, pp.87~101 (2005)
43. D'Amelio P, "The use of raloxifene in osteoporosis treatment", Expert Opin Pharmacother, 14, pp.949~956 (2013)
44. Gennari L, "Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy", Expert Opin Pharmacother, 10, pp.2209~2220 (2009)
45. Ke HZ, "Effects of CP-336,156, a new, nonsteroidal estrogen agonist", antagonist, on bone, serum cholesterol, uterus and body composition in rat models, 1998, pp.139, 2068~2076
46. Cummings SR, "Lasofoxifene in postmenopausal women with osteoporosis", N Engl J Med, 362, pp.686~696 (2010)
47. Goldstein SR, "Postmenopausal evaluation and risk reduction with lasofoxifene (PEARL) trial: 5-year gynecological outcomes", Menopause, 18, pp.17~22 (2011)
48. Ensrud K, "Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the postmenopausal evaluation and risk reduction with lasofoxifene (PEARL) trial", Circulation, 122, pp.1716~1724 (2010)
49. Komm BS, "Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity", Endocrinology, 146, pp.3999~4008 (2005)
50. Silverman SL, "Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis:Results from a 3-year, randomized, placebo-, and active-controlled clinical trial", J Bone Miner Res, 23, pp.1923~1934 (2008)
51. Silverman SL, "Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis:Results of a 5-year, randomized, placebocontrolled study", Osteoporos Int, 23, pp.351~363 (2012)
52. Kaufman JM, "An evaluation of the fracture risk assessment tool (FRAX(R)) as an indicator of treatment efficacy: The effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX(R)", Osteoporos Int, 24, pp.2561~2569 (2013)
53. Claus Christiansen, "Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis", BMC Musculoskeletal Disorders, 11(1) (2010), Springer Nature[DOI]
54. ios S, "Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: Results of a 7-year, randomized, placebo-controlled, phase 3 study", Maturitas, 76, pp.81~87 (2013)
55. Stovall DW, "The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety", Menopause, 14, pp.510~517 (2007)
56. Archer DF, "Bazedoxifene", conjugated estrogens (BZA, Fertil Steril, pp.2009, 92[DOI]
57. Lindsay R, "Efficacy of tissue-selective estrogen complex of bazedoxifene", conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women, 2009, pp.92, 1045~1052
58. Lobo RA, "Evaluation of bazedoxifene", conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile, 2009, pp.92, 1025~1038
59. Pickar JH, "Endometrial effects of a tissue selective estrogen complex containing bazedoxifene", conjugated estrogens as a menopausal therapy, 2009, pp.92, 1018~1024
60. Komm BS, "Development of conjugated estrogens", bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss, 2014, pp.90, 71~81
61. Komi J, "Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women", Menopause, 12, pp.202~209 (2005)
62. Rutanen EM, "Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: A double-blind, randomized trial", Menopause, 10, pp.433~439 (2003)
63. Soe LH, "Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy:Potential benefits in bone and breast", Int J Womens Health, 5, pp.605~611 (2013)
64. Constantine GD, "Endometrial safety of ospemifene: Results of the phase 2", 3 clinical development program, 2015, pp.22, 36~43
65. Komi J, "Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women", Gynecol Endocrinol, 18, pp.152~158 (2004)
66. Komi J, "Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women", J Bone Miner Metab, 24, pp.314~318 (2006)
67. Ylikorkala O, "Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women", Menopause, 10, pp.440~447 (2003)
68. Simon JA, "One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus", Menopause, 20, pp.418~427 (2013)
69. Gutman M, "Comparison of the effects of EM-652(SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice", Int J Cancer, 99, pp.273~278 (2002)
70. Wardell SE, "Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader", Endocr Relat Cancer, 22 (2015)
71. Mao C, "A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells", J Biol Chem, 283, pp.12819~12830 (2008)

관련 논문AI추천